Personalized peptide vaccination as second‐line treatment for metastatic upper tract urothelial carcinoma
Open Access
- 12 October 2017
- journal article
- research article
- Published by Wiley in Cancer Science
- Vol. 108 (12) , 2430-2437
Abstract
This study investigated the applicability of personalized peptide vaccination (PPV) for patients with metastatic upper tract urothelial cancer (mUTUC) after failure of platinum‐based chemotherapy. In this single arm, open‐label, phase II clinical trial, patients with mUTUC received PPV at a single institution. Personalized peptide vaccination treatment used a maximum of four peptides chosen from 27 candidate peptides according to human leukocyte antigen types and peptide‐reactive IgG titers, for six s.c. injections weekly as one cycle. The safety of PPV, as well as its influence on host immunity and effect on overall survival were assessed. Forty‐eight patients were enrolled in this study. Personalized peptide vaccinations were well tolerated without severe adverse events. Median survival time was 7.3 months (95% confidence interval [CI], 5.3–13.1) with 13.0 months for patients receiving combined salvage chemotherapy (95% CI, 5.7–17.5) and 4.5 months for patients receiving PPV alone (95% CI, 1.7–10.1) (P = 0.080). Patients with positive CTL responses showed a significantly longer survival than patients with negative CTL responses (hazard ratio, 0.37; 95% CI, 0.16–0.85; P = 0.019). Multivariate Cox regression analysis showed that lower numbers of Bellmunt risk factors and lower levels of B‐cell activating factor were significantly associated with favorable overall survival for patients under PPV treatment. This study indicated that PPV for patients with mUTUC after failure of platinum‐based chemotherapy induced substantial peptide‐specific CTL responses without severe adverse events and has the potential to prolong survival when combined with salvage chemotherapy.UMIN Clinical Trials Registry ID: 000001854.Keywords
Funding Information
- Japan Society for the Promotion of Science (JP15K10614)
- Japan Agency for Medical Research and Development
- Ministry of Education, Culture, Sports, Science and Technology
This publication has 27 references indexed in Scilit:
- Safety and Activity of Anti–PD-L1 Antibody in Patients with Advanced CancerNew England Journal of Medicine, 2012
- Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in CancerNew England Journal of Medicine, 2012
- Guía clínica para el diagnóstico y tratamiento de los carcinomas de las células uroteliales de las vías urinarias superiores: actualización de 2011Actas Urológicas Españolas, 2012
- A phase I study of personalized peptide vaccination for advanced urothelial carcinoma patients who failed treatment with methotrexate, vinblastine, adriamycin and cisplatinBJU International, 2010
- Prognostic Factors in Patients With Advanced Transitional Cell Carcinoma of the Urothelial Tract Experiencing Treatment Failure With Platinum-Containing RegimensJournal of Clinical Oncology, 2010
- A Critical Appraisal of the Value of Lymph Node Dissection at Nephroureterectomy for Upper Tract Urothelial CarcinomaUrology, 2010
- Outcomes of radical nephroureterectomy: A series from the Upper Tract Urothelial Carcinoma CollaborationCancer, 2009
- Immunological evaluation of neoadjuvant peptide vaccination before radical prostatectomy for patients with localized prostate cancerThe Prostate, 2007
- Immunologic Evaluation of Personalized Peptide Vaccination for Patients with Advanced Malignant GliomaClinical Cancer Research, 2005
- BAFF-R, a Newly Identified TNF Receptor That Specifically Interacts with BAFFScience, 2001